RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia
May 1, 2026
Mariana Silva‐Carvalho, Andreia Machado Brito-Da-Costa, Ricardo Dinis-Oliveira et al.
Psilocybin, psilocin, 5-MeO-DMT, LSD and mescaline are classical hallucinogens whose recreational use has increased over recent decades (Brito-da-Costa et al., 2021; Dinis-Oliveira et al., 2019; Holze et al., 2021; Jiang et al., 2013). However, data on their interactions with cytochrome P450 (CYP450) enzymes remain scarce, despite the potential for clinically relevant drug–drug interactions....
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia
May 1, 2026
Andreia Machado Brito-Da-Costa, Francisco Sacadura, Ricardo Jorge Dinis-Oliveira et al.
Introduction: Psilocybin, the main psychoactive compound in Psilocybe mushrooms, has attracted interest for its potential therapeutic effects in neuropsychiatric disorders (Erkizia-Santamaría et al., 2025). However, preclinical data comparing its behavioral properties to whole mushroom extracts remain limited (Ali et al., 2023; Johnson-Groh, 2025). Objective: To investigate the reinforcing and...
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia
May 1, 2026
Andreia Machado Brito-Da-Costa, Mariana Carvalho, Ricardo Jorge Dinis-Oliveira et al.
Psilocybin is a hallucinogen produced by “magic mushrooms”, being rapidly metabolized in the organism into psilocin (Brito-da-Costa et al., 2022; Dinis-Oliveira, 2017). A scientific gap exists regarding the possible interactions between psilocybin/psilocin and CYP450 enzymes. Given their biological importance and since the binding of drugs to CYP450 enzymes can interfere with the metabolism of...
SLEEPJ
May 1, 2026
Matthew J Reid, Eli Weisman, Luis Luna Martinez et al.
Despite evidence of an acute effect of psilocybin on sleep physiology, its enduring effects beyond the period of acute administration and active metabolism remain unexplored. Within a clinical trial of psilocybin-assisted therapy for alcohol use disorder comorbid with major depressive disorder, we monitored sleep for ten continuous nights (3 pre-dose | 7 post-dose) in participants (N=22)...
SLEEPJ
May 1, 2026
Matthew J Reid, Abigail Yaffe, Ian Geithner et al.
Post-treatment Lyme Disease (PTLD) is a post-infectious syndrome characterized by fatigue, hypersomnia, sleep-disturbance, musculoskeletal pain and/or cognitive difficulties. As part of an open-label pilot study of psilocybin-assisted treatment for PTLD, we explored potential for psilocybin-assisted treatment to remedy sleep-related disturbances in this population. 12 participants consented to...
American Journal of Respiratory and Critical Care Medicine
May 1, 2026
Louise Hecker, Jennifer Kleinhenz, Cristian Coarfa et al.
The elderly population is rapidly growing. Overwhelming epidemiologic data has demonstrated worse health outcomes with increasing age for a multitude of lung diseases (COVID being one of numerous examples). There is an increasingly urgent need for a more complete understanding of the molecular pathways and biological processes underlying aging to improve outcomes for age-associated lung...
Sleep
May 1, 2026
Denise C. Vidot, Bria-Necole Diggs, Amrit Baral et al.
Abstract Introduction Psychedelic use and interest in its therapeutic potential are rapidly increasing; yet its relationship with insomnia remains poorly understood. This study aims to estimate differences in insomnia severity by type of psychedelic consumed among a cohort of 18-to-35-year olds. Methods Data are from the Herbal Heart Study - Sleep Ancillary (N=100) cannabis consumers....
Molecular Psychiatry
May 1, 2026
Sixtine Fleury, Katherine M. Nautiyal
4 citations
Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin binds to many serotonin receptor...
JOURNAL OF ADVANCE AND FUTURE RESEARCH
May 1, 2026
Gyandev Gupta, Ravina Yadav
Depression is one of the most common mental health challenges people face today. It goes beyond just feeling sad — it shapes the way a person thinks, behaves, and experiences the world around them. The persistent low mood, the fading interest in things that once brought joy, the fog that makes even simple decisions feel overwhelming — all of it quietly chips away at a person's quality of life....
Nature Mental Health
May 1, 2026
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
2 citations
This study presents a living systematic review and open-data meta-analytic database from 15 randomized controlled trials examining the effects of psilocybin treatment on depressive symptoms. Existing evidence suggests that psilocybin treatment alleviates depressive symptoms. Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we...